Determination of balance, fall risk, and kinesiophobia in individuals with Alzheimer’s Dementia DOI Creative Commons

Oğuzhan Doğancı,

Meral Sertel

Frontiers in Psychology, Journal Year: 2025, Volume and Issue: 16

Published: March 11, 2025

Objective This study aimed to determine balance, fall risk, and kinesiophobia in individuals with Alzheimer’s Dementia (AD). Methods The was completed 18 AD healthy AD-free control group early or moderate-stage diagnosed by a neurologist. Socio-demographic characteristics of the were assessed using an evaluation form, their balance evaluated Tinetti Balance Gait Assessment Test, Timed Up Go Single Leg Standing Test. Falls Risk Self-Assessment Scale (FRSAS) used assess risk falls. Kinesiophobia Tampa for (TKS). Additionally, participants underwent Mini-Mental State Examination (MMSE). Result mean age lower than that individuals, means 69 ± 3.66 years 65.4 4.10 years, respectively ( p = 0.012). 0.005), gait < 0.001), total (MMSE) 0,001) scores relative controls. FRSAS 0.001) higher TKS found be similar between 0.860). Conclusion It disease (AD) have poorer falls compared individuals. In light these results, assessments should included when developing rehabilitation protocols AD. Treatment designed this patient must incorporate balance-specific exercise training programs. individual environmental preventive measures implemented reduce Clinical trial registration Trial Number: NCT05201768.

Language: Английский

Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications DOI
Niraj Kumar Jha, Niraj Kumar Jha, Mohana Vamsi Nuli

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 98, P. 102224 - 102224

Published: Feb. 10, 2024

Language: Английский

Citations

14
Role of histone modifications in neurogenesis and neurodegenerative disease development DOI
Anqi Zhao,

Wenhong Xu,

Rui Han

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 98, P. 102324 - 102324

Published: May 16, 2024

Language: Английский

Citations

13
Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review DOI Creative Commons
J Yang,

Weijia Zhi,

Lifeng Wang

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(12), P. 2812 - 2812

Published: June 13, 2024

Tau protein is a microtubule-associated that widely distributed in the central nervous system and maintains regulates neuronal morphology function. aggregates abnormally forms neurofibrillary tangles neurodegenerative diseases, disrupting structure function of neurons leading to death, which triggers initiation progression neurological disorders. The aggregation tau diseases associated with post-translational modifications, may affect hydrophilicity, spatial conformation, stability protein, promoting formation tangles. Therefore, studying role mechanism aberrant important for understanding finding therapeutic approaches. This review describes possible mechanisms by promotes modifications influencing factors, current status drug discovery development related contribute new approaches alleviate or treat diseases.

Language: Английский

Citations

13
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system DOI Creative Commons
Jiaqi Mei,

Yi Li,

Liyan Niu

et al.

Translational Neurodegeneration, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 9, 2024

The rising prevalence of diabetes mellitus has casted a spotlight on one its significant sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for management, are increasingly studied their benefits. These benefits may include reduction oxidative stress and neuroinflammation, decrease amyloid burdens, enhancement neuronal plasticity, improved cerebral glucose utilization. multifaceted effects the relatively favorable side-effect profile SGLT2 inhibitors render them promising therapeutic candidate disorders. Nonetheless, application impairment is not without limitations, necessitating more comprehensive research to fully determine potential treatment. In this review, we discuss role in neural function, elucidate diabetes-cognition nexus, synthesize current knowledge based animal studies clinical evidence. Research gaps proposed spur further investigation.

Language: Английский

Citations

13
Promoting Alzheimer’s disease research and therapy with stem cell technology DOI Creative Commons

Zimeng Cao,

Fanshu Kong,

Jiaqi Ding

et al.

Stem Cell Research & Therapy, Journal Year: 2024, Volume and Issue: 15(1)

Published: May 7, 2024

Abstract Background Alzheimer’s disease (AD) is a prevalent form of dementia leading to memory loss, reduced cognitive and linguistic abilities, decreased self-care. Current AD treatments aim relieve symptoms slow progression, but cure elusive due limited understanding the underlying mechanisms. Main content Stem cell technology has potential revolutionize research. With ability self-renew differentiate into various types, stem cells are valuable tools for modeling, drug screening, therapy. Recent advances have broadened our beyond deposition amyloidβ (Aβ) or tau proteins in encompass risk genes, immune system disorders, neuron–glia mis-communication, relying heavily on cell-derived models. These cell-based models (e.g., organoids microfluidic chips) simulate vivo pathological processes with extraordinary spatial temporal resolution. technologies alleviate pathology through pathways, including immunomodulation, replacement damaged neurons, neurotrophic support. In recent years, transplantation glial like oligodendrocytes infusion exosomes become hot research topics. Conclusion Although therapies face several challenges, such as extended culture time low differentiation efficiency, they still show considerable treatment likely preferred

Language: Английский

Citations

12
Unraveling the therapeutic potential of quercetin and quercetin-3-O-glucuronide in Alzheimer's disease through network pharmacology, molecular docking, and dynamic simulations DOI Creative Commons
Sarvesh Sabarathinam

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: June 27, 2024

Abstract Quercetin is a flavonoid with notable pharmacological effects and promising therapeutic potential. plays significant role in neuroinflammation, which helps reduce Alzheimer's disease (AD) severity. (Q) quercetin 3-O-glucuronide (Q3OG) are some of the most potent antioxidants available from natural sources. However, form converted into Q3OG when reacted intestinal microbes. The study aims to ensure potential Q Q3OG. In this study, molecular targets were first identified using Swiss Target Prediction platform pathogenic AD DisGeNET database. Followed by compound target overlapping, 77 placed that AKT1, EGFR, MMP9, TNF, PTGS2, MMP2, IGF1R, MCL1, MET PARP1 was top-ranked target, estimated CytoHubba plug-in. Molecular docking performed for towards PDB:1UNQ target. binding score − 6.2 kcal/mol 6.58 respectively. dynamics simulation conducted at 200 ns. This study's results help identify multiple sites bioactive compounds. Thus, synthesizing new chemical entity-based on structural modification may aid eradicating complications.

Language: Английский

Citations

11
Mind Gaps and Bone Snaps: Exploring the Connection Between Alzheimer’s Disease and Osteoporosis DOI Creative Commons

Hannah S. Wang,

Sonali Karnik, Tyler J. Margetts

et al.

Current Osteoporosis Reports, Journal Year: 2024, Volume and Issue: 22(5), P. 483 - 494

Published: Jan. 18, 2024

Abstract Purpose of Review This comprehensive review discusses the complex relationship between Alzheimer’s disease (AD) and osteoporosis, two conditions that are prevalent in aging population result adverse complications on quality life. The purpose this is to succinctly elucidate many commonalities conditions, including shared pathways, inflammatory oxidative mechanisms, hormonal deficiencies. Recent Findings AD osteoporosis share aspects their respective disease-defining pathophysiology. These include amyloid beta deposition, Wnt/β-catenin signaling pathway, estrogen deficiency. mechanisms risk factors associated with a large percentage patients develop both diseases. Previous literature has established progression increases sustaining fracture. findings demonstrate reverse may also be true, suggesting fracture early life course can predispose one developing due activation these mechanisms. discovery further guides development novel therapeutics which targeted. Summary detailed delves into uncover players bring seemingly unrelated together. discussion throughout ultimately posits occurrence fractures mechanism behind healing later life, similar how at an increased fractures. By focusing better understand individually as unit, thus informing therapeutic approaches research. article part series multiple manuscripts designed determine utility using artificial intelligence for writing scientific reviews.

Language: Английский

Citations

10
Protective effect of flavonoids on oxidative stress injury in Alzheimer’s disease DOI
Kaixuan Wang, Xinmei Chen

Natural Product Research, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 28

Published: June 23, 2024

Alzheimer's disease (AD) is the most common neurodegenerative disease, which mainly caused by damage of structure and function central nervous system. At present, there are many adverse reactions in market-available drugs, can't significantly inhibit occurrence AD. Therefore, current focus research to find safe effective therapeutic drugs improve clinical treatment Oxidative stress bridges different mechanism hypotheses AD plays a key role Numerous studies have shown that natural flavonoids good antioxidant effects. They can directly or indirectly resist ­oxidative stress, Aβ aggregation Tau protein hyperphosphorylation activating Nrf2 other oxidation-antioxidation-related signals, regulating synaptic function-related pathways, promoting mitochondrial autophagy, etc., play neuroprotective In this review, we summarised inhibiting oxidative injury recent years. Moreover, because shortcomings poor biofilm permeability low bioavailability flavonoids, advantages progress nano-drug delivery systems such as liposomes solid lipid nanoparticles were highlighted. We hope review provides useful way explore treatments.

Language: Английский

Citations

9
Ghrelin Induces Ferroptosis Resistance and M2 Polarization of Microglia to Alleviate Neuroinflammation and Cognitive Impairment in Alzheimer’s Disease DOI

Yaoxue Guo,

Junli Zhao, Yizhi Liu

et al.

Journal of Neuroimmune Pharmacology, Journal Year: 2025, Volume and Issue: 20(1)

Published: Jan. 11, 2025

Language: Английский

Citations

1
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice DOI Creative Commons
Yuanyu Shen, Xiaolei Zhang, Si-qi Liu

et al.

Alzheimer s Research & Therapy, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 13, 2025

The imbalance of glutamate (Glu) and gamma-aminobutyric acid (GABA) neurotransmitter system plays a crucial role in the pathogenesis Alzheimer's disease (AD). Riluzole is Glu modulator originally approved for amyotrophic lateral sclerosis that has shown potential neuroprotective effects various neurodegenerative disorders. However, whether riluzole can improve GABA homeostasis AD brain its related mechanism action remain unknown. This study utilized chemical exchange saturation transfer (CEST) imaging combined with proton magnetic resonance spectroscopy (1H-MRS) to monitor dynamic changes riluzole-treated mice, aiming evaluate efficacy treatment. GluCEST, GABACEST 1H-MRS were used longitudinally levels 3xTg mice treated (12.5 mg/kg/day) or vehicle 20 weeks. Magnetic measurements performed at baseline, 6, 12, weeks post-treatment. Cognitive performance was assessed using Morris Water Maze (MWM) 10, At endpoint, immunohistochemistry, Nissl staining, Western blot pathology, neuronal survival, protein expression. consistently revealed higher compared untreated controls, which associated improvements spatial learning memory. cognitive significantly correlated increased GluCEST signals levels. Immunohistochemistry staining demonstrated treatment reduced amyloid-beta (Aβ) deposition, tau hyperphosphorylation, GFAP-positive astrocyte activation, prevented loss. Moreover, upregulated expression excitatory amino transporter 2 (EAAT2), glutamic decarboxylase 65/67 (GAD65/67), glutamine synthetase (GS), suggesting enhanced metabolism. CEST effectiveness modulating Glu- GABA-related improving function potentially through regulating key proteins involved These findings suggest as therapeutic agent highlight utility multimodal MR monitoring response exploring mechanisms.

Language: Английский

Citations

1